Dental Monitoring Application: it is a valid innovation in the Orthodontics Practice?

AIM: The aim of research is to show the effectiveness of 0.014X0.025 CuNiTi wires in self-ligating straight-wire appliance in the working time of 10 weeks, the treatments are monitored with the Dental Monitoring® Applications. A statistical significance analysis of the correspondence between the results of the first phase of fixed orthodontic treatment (alignment), according to the type of wires used, compared to the time (about 8 weeks) suggested by the manufactory house is therefore useful to fully understand the power of these arches in the orthodontic treatment. MATERIAL AND METHODS: The study provides for the recruitment of 35 cooperating patients with different degrees of crowding, all treated with Damon System(ORMCO), monitoring them through pictures, taken in the Dental Monitoring(DM®) sequence technique, as follows: Time0: Arch-Wire Insertion (0.014x0.025CuNiTi), Time1: Four Weeks, Time2: Eight Weeks, Time3: Ten Weeks. RESULT: The results obtained will be compared with records reported by manufactory house. Our results showed that the manufacture information does not correspond to the real efficiency of the device tested. Statistical Analyses performed by T test student. CONCLUSIONS: In Our experience, applying DM Application with self-ligating technique has reduced in term of number of appointments for each patient from 3 appointments in 10 weeks to 2 appointments, when the indirect bonding was effectuated and when we have inserted a 014X025 CuNiTi. This means that there is a reduction in the mean period of chair time, of material 'costs, number of visits; moreover, there is an increase in term of frequency of patient' s monitoring, resulting in a more precise evaluation of treatment by orthodontist. The limits of the present study are presented by the variable patient's compliance and by the small number of patients. This device is an instrument advantageous for the orthodontist's work. In literature, there are few articles inherent to Digital application Mobile, we will hope that this our experience represents a valid support to a major use of this application in the clinical practice.

Prospective clinical trial to compare vincristine and vinblastine in a COP-based protocol for lymphoma in cats.

BACKGROUND: Current standard chemotherapy protocols for lymphoma in cats carry risks of gastrointestinal toxicity, which can decrease quality of life and complicate response assessment. Protocols with less gastrointestinal toxicity may improve treatment tolerance. HYPOTHESIS/OBJECTIVES: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine or vinblastine as part of combination chemotherapy for lymphoma. We hypothesized that vinblastine would have similar efficacy, but less gastrointestinal toxicity, compared with vincristine. ANIMALS: Forty client-owned cats with confirmed diagnosis of lymphoma. METHODS: Cats were randomized to 1 of 2 treatment arms and received weekly COP-based chemotherapy for 6 months or until disease progression. Response rate, progression-free survival (PFS), lymphoma-specific survival (LSS), and incidence and severity of gastrointestinal and hematologic toxicity were compared between arms. Arm cross-over occurred if specific gastrointestinal toxicity criteria were noted. RESULTS: Cats in both arms had similar response rates, PFS, and LSS (48 versus 64 days, P = .87; 139 versus 136 days, P = .96). Cats that received vincristine were significantly more likely to switch arms based on gastrointestinal toxicity than cats that received vinblastine (44.4 versus 10.5%, P = .02). Lower baseline weight was significantly negatively associated with PFS and LSS (P = .01, P = .003, respectively). Baseline anemia was significantly negatively associated with LSS (P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that vinblastine is a reasonable alternative to vincristine in the treatment of some cats with lymphoma. Baseline body weight remains a significant prognostic factor for cats with lymphoma.